QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:ATRC

AtriCure (ATRC) Stock Price, News & Analysis

$33.56
-0.44 (-1.29%)
(As of 02/23/2024 ET)
Today's Range
$32.91
$34.00
50-Day Range
$31.71
$37.31
52-Week Range
$29.67
$59.61
Volume
412,571 shs
Average Volume
559,629 shs
Market Capitalization
$1.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.57

AtriCure MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
65.2% Upside
$55.57 Price Target
Short Interest
Bearish
4.66% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of AtriCure in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.71) to ($0.44) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.31 out of 5 stars

Medical Sector

544th out of 939 stocks

Surgical & Medical Instruments Industry

66th out of 93 stocks


ATRC stock logo

About AtriCure Stock (NASDAQ:ATRC)

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

ATRC Stock Price History

ATRC Stock News Headlines

AtriCure (NASDAQ:ATRC) Downgraded to "Sell" at StockNews.com
Elon Musk's "Project Dojo" is a Game-Changer
Morgan Stanley predicts that Musk's latest act will boost Tesla's shares by 80% in the next 12 months. But if you want to profit from this development, you'll buy the firm that could see its sales explode by 829% as "Project Dojo" sweeps the nation.
UBS Group Boosts AtriCure (NASDAQ:ATRC) Price Target to $58.00
Stifel Nicolaus Trims AtriCure (NASDAQ:ATRC) Target Price to $42.00
AtriCure (NASDAQ:ATRC) Stock Price Down 6% on Analyst Downgrade
AtriCure Full Year 2023 Earnings: EPS Beats Expectations
Discover Lexagene - Open to Accredited Investors Only
Get access to significant growth potential in a rapidly scaling biopharma market
AtriCure price target raised by $1 at UBS, here's why
Cracking The Code: Understanding Analyst Reviews For AtriCure
Recap: AtriCure Q4 Earnings
AtriCure Q4 2023 Earnings Preview
AtriCure's Earnings: A Preview
Atricure’s Strong Growth and Positive Outlook Justify Buy Rating
Key Takeaways From AtriCure Analyst Ratings
See More Headlines
Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
2/23/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ATRC
CUSIP
04963C20
Employees
1,050
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$55.57
High Stock Price Target
$68.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+64.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-30,440,000.00
Pretax Margin
-7.48%

Debt

Sales & Book Value

Annual Sales
$399.24 million
Book Value
$9.80 per share

Miscellaneous

Free Float
46,160,000
Market Cap
$1.60 billion
Optionable
Optionable
Beta
1.40

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report














ATRC Stock Analysis - Frequently Asked Questions

Should I buy or sell AtriCure stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings
or view top-rated stocks.

What is AtriCure's stock price target for 2024?

5 equities research analysts have issued 12 month target prices for AtriCure's stock. Their ATRC share price targets range from $42.00 to $68.00. On average, they predict the company's share price to reach $55.57 in the next twelve months. This suggests a possible upside of 65.2% from the stock's current price.
View analysts price targets for ATRC
or view top-rated stocks among Wall Street analysts.

How have ATRC shares performed in 2024?

AtriCure's stock was trading at $35.69 at the beginning of the year. Since then, ATRC shares have decreased by 5.8% and is now trading at $33.63.
View the best growth stocks for 2024 here
.

Are investors shorting AtriCure?

AtriCure saw a increase in short interest in January. As of January 31st, there was short interest totaling 2,220,000 shares, an increase of 15.0% from the January 15th total of 1,930,000 shares. Based on an average daily volume of 547,700 shares, the days-to-cover ratio is currently 4.1 days.
View AtriCure's Short Interest
.

When is AtriCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our ATRC earnings forecast
.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) released its earnings results on Thursday, February, 15th. The medical device company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01. The medical device company earned $106.50 million during the quarter, compared to the consensus estimate of $103.68 million. AtriCure had a negative trailing twelve-month return on equity of 7.55% and a negative net margin of 7.62%. The firm's revenue for the quarter was up 21.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.09) earnings per share.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure updated its FY 2024 earnings guidance on Monday, January, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $459.0 million-$466.0 million, compared to the consensus revenue estimate of $454.7 million.

What is Michael Carrel's approval rating as AtriCure's CEO?

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

What other stocks do shareholders of AtriCure own?
Who are AtriCure's major shareholders?

AtriCure's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.05%), First Light Asset Management LLC (2.85%), Nuveen Asset Management LLC (2.16%), Dimensional Fund Advisors LP (2.11%), TimesSquare Capital Management LLC (2.06%) and Fiera Capital Corp (1.86%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Karen Prange, Karl S Dahlquist, Maggie Yuen, Mark A Collar, Mark A Collar, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends
.

How do I buy shares of AtriCure?

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does AtriCure have any subsidiaries?
The following companies are subsidiares of AtriCure: SentreHEART.
Read More
This page (NASDAQ:ATRC) was last updated on 2/23/2024 by MarketBeat.com Staff